Abstract B069: Pharmacodynamic evidence of Wnt/β-catenin inhibition by tegavivint, a TBL1-directed transcriptional modulator, in advanced hepatocellular carcinoma: a phase 1 study
An integrated analysis of preclinical and clinical pharmacodynamic data characterizing tegavivint activity establishes TBL1 as a clinically actionable regulator of oncogenic transcription and demonstrates that tegavivint achieves pharmacodynamic modulation of the Wnt pathway through a differentiated downstream mechanis...